Sequence: HAIYPRH
| Experiment Id | EXP002530 |
|---|---|
| Paper | Brain tumor-targeted therapy by systemic delivery of siRNA with transferrin receptor-mediated core-s |
| Peptide | T7 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | Peptide density 5 mol% of total lipids |
| Rna Concentration | 100 nM |
| Mixing Ratio | Layer-by-layer assembly (core–shell) |
| Formulation Format | T7-modified core–shell nanoparticle (T7-LPC/siRNA) |
| Formulation Components | T7-PEG-DSPE + liposome + protamine/CS/siRNA core |
| Size Nm | 84.00 |
| Zeta Mv | 34.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | BMVECs; U87 glioma cells |
| Animal Model | |
| Administration Route | |
| Output Type | Gene knockdown and BBB penetration (co-culture) |
| Output Value | Strong EGFR mRNA and protein reduction |
| Output Units | |
| Output Notes | TfR-mediated uptake enhanced vs PEG control |
| Toxicity Notes | Reduced toxicity after PEGylation |
| Curation Notes |